Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report

INTRODUCTION: Pembrolizumab and other immune checkpoint inhibitors are the emerging treatment for selected, high-grade malignancies. However, a small number of patients are unable to tolerate its adverse effects, leading to discontinuation of this potentially life-changing therapy. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Chia-Yi, Ou, Yang-Hao, Chang, Shih-Liang, Lin, Chih-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086081/
https://www.ncbi.nlm.nih.gov/pubmed/33926558
http://dx.doi.org/10.1186/s13256-021-02722-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086081/
https://www.ncbi.nlm.nih.gov/pubmed/33926558
http://dx.doi.org/10.1186/s13256-021-02722-8

Ejemplares similares